Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

Verastem, Inc. (NASDAQ:VSTM) is one of the 11 Best Short Squeeze Stocks to Buy Now.

The company progresses with its Phase 3 ovarian cancer trial while AVMAPKI FAKZYNJA CO-PACK generates revenue.

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

A doctor consulting a patient about the efficacy of the biopharmaceutical company’s drugs.

Verastem, Inc. (NASDAQ:VSTM), operating from its headquarters in Massachusetts, is a development-stage biopharmaceutical company. Its focus is on discovering and commercializing novel cancer therapies, particularly those targeting cancer stem cells and RAS pathway–based malignancies.

On August 8, 2025, Verastem, Inc. (NASDAQ:VSTM) announced an update Phase 3 study in ovarian cancer. The company is engaged in a Phase 3 clinical trial, RAMP 301, to test a new combination therapy for recurrent low-grade serous ovarian cancer (LGSOC).

It announced that the study will focus on assessing the safety and effectiveness of the oral drugs avutometinib and defactinib against standard treatments. It’s an open-label, randomized trial, and participants can switch to the new drugs if their disease progresses. The study, which began in March 2024, is crucial for exploring new treatment options for this challenging cancer. It has the potential to impact on the competitive environment in oncology.

Additionally, in its earnings call, Verastem, Inc. (NASDAQ:VSTM) also highlighted securing FDA approval for its AVMAPKI FAKZYNJA CO-PACK nearly two months ahead of schedule. With this approval, the company enters the first-ever treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). The product helped generate $2.1 million in net product revenue within just six weeks of its launch.

The company has a short float of 37.03%, suggesting elevated bearish bets that position the stock for significant gains if a bullish trigger were to materialize.

While we acknowledge the risk and potential of VSTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VSTM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon

Disclosure. None.